Market News (Page 82) - TendieTensor

Market News Page 82 of 162 • 4,027 articles

CRMT Investor News: If You Have Suffered Losses in America’s Car-Mart, Inc. (NASDAQ: CRMT), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

GlobeNewswire Inc. • Rosen Law Firm

CRMT Investor News: If You Have Suffered Losses in America’s Car-Mart, Inc. (NASDAQ: CRMT), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

11/08/2025 04:51 PM • Rosen Law Firm is investigating potential securities claims for Car-Mart shareholders after the company reported a significant first-quarter loss and stock price decline.

VOO - Recommended as a broad market index fund, though noted for concentration risk with top 10 holdings representing 39% of fund value
CRMT - Stock dropped 18.2% after reporting a first-quarter loss of 69 cents per share, compared to a 15 cents per share loss in the previous year, indicating deteriorating financial performance

#securities claims #investor losses #stock performance

Stan Taylor Launches The Black Book of Power, Calling for a Consciousness Shift as 60,000 Readers Embrace Counter-Manipulation Training

GlobeNewswire Inc. • Stan Taylor

Stan Taylor Launches The Black Book of Power, Calling for a Consciousness Shift as 60,000 Readers Embrace Counter-Manipulation Training

11/08/2025 04:02 PM • Stan Taylor, a communications specialist, launches a book revealing psychological manipulation techniques, helping professionals understand power dynamics and counter-manipulation strategies.

MSFT - A Microsoft senior engineer was mentioned as an example of someone who decoded organizational power structures, with no negative or overtly positive context

#manipulation #power dynamics #persuasion #consciousness #self-improvement

ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR

GlobeNewswire Inc. • Rosen Law Firm

ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR

11/08/2025 03:33 PM • Rosen Law Firm is investigating potential securities claims for aTyr Pharma investors who purchased stock between January 16 and September 12, 2025, alleging false statements about drug Efzofitimod's efficacy.

XLK - High historical returns with 22.8% average annual gains over past decade, diverse technology sector exposure
ATYR - Lawsuit alleges company disseminated false and misleading statements about drug efficacy, potentially causing investor damages

#securities class action #investor rights #pharmaceutical litigation

MOH FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Molina Healthcare, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MOH

GlobeNewswire Inc. • Rosen Law Firm

MOH FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Molina Healthcare, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MOH

11/08/2025 02:35 PM • Rosen Law Firm alerts Molina Healthcare investors about a securities class action lawsuit regarding potential financial misrepresentations during February-July 2025, with a December 2, 2025 lead plaintiff deadline.

SCHD - Combines solid dividend yield with impressive growth performance, tracking 100 stocks with consistent dividend history
MOH - Lawsuit alleges the company failed to disclose material adverse facts about medical cost trends, financial guidance, and potentially misleading statements about business operations and prospects

#securities #class action #investor rights #financial disclosure

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

GlobeNewswire Inc. • Lexicon Pharmaceuticals

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

11/08/2025 02:30 PM • A clinical study demonstrated sotagliflozin's potential benefits for heart failure patients with preserved ejection fraction (HFpEF) without diabetes, showing significant improvements in cardiac structure, function, and quality of life.

LXRX - The company presented promising clinical trial results for sotagliflozin, showing potential therapeutic benefits in a new patient population, which could expand the drug's market and commercial potential

#sotagliflozin #heart failure #HFpEF #clinical trial #cardiac health

Prediction: Nvidia Stock Is Going to Stall Out on Nov. 20

The Motley Fool • Adria Cimino

Prediction: Nvidia Stock Is Going to Stall Out on Nov. 20

11/08/2025 02:10 PM • Nvidia, a leading AI chip designer, is expected to potentially experience stock momentum stagnation after its Q3 earnings report on Nov. 19, despite strong financial performance and AI market leadership.

NVDA - While the company has strong financial performance and AI market leadership, the article predicts a potential short-term stock momentum stall due to market concerns about AI valuation bubbles and recent stock behavior after earnings reports

#Nvidia #AI #earnings #stock prediction #semiconductor #technology

3 Dividend Stocks With Yields Between 5.8% and 7.6% to Power Your Passive Income Stream in 2026

The Motley Fool • Matt Dilallo

3 Dividend Stocks With Yields Between 5.8% and 7.6% to Power Your Passive Income Stream in 2026

11/08/2025 01:33 PM • The article highlights three high-yielding dividend stocks - Realty Income, Enterprise Products Partners, and Main Street Capital - that offer stable and growing passive income streams with dividend yields ranging from 5.8% to 7.6%.

AMZN - Fairly valued, part of Magnificent Seven stocks, operating in multiple sectors with consistent growth potential
O - Has consistently raised monthly dividends 132 times since 1994, owns a diversified commercial property portfolio with stable cash flow, and maintains a conservative dividend payout ratio

#dividend stocks #passive income #high yield #monthly dividends #REITs #MLPs

TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

GlobeNewswire Inc. • Rosen Law Firm

TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

11/08/2025 01:26 PM • Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care due to a voluntary medical device correction for t:slim X2 insulin pumps that caused a significant stock price drop.

BCpA - Reported unit sales up 6%, revenue up 15%, record market share, and positive outlook for 2026
TNDM - Stock dropped 19.9% after announcing a voluntary medical device correction that could potentially interrupt insulin delivery, suggesting significant product and financial risk

#securities claim #medical device #investor losses #class action

As Cash Continues to Pile Up, Should Investors Buy Berkshire Hathaway Stock or Stay Away?

The Motley Fool • Geoffrey Seiler

As Cash Continues to Pile Up, Should Investors Buy Berkshire Hathaway Stock or Stay Away?

11/08/2025 01:23 PM • Berkshire Hathaway continues to be cautious in the stock market, selling more stocks than buying and accumulating a record $381.6 billion in cash. Warren Buffett sees the market as overvalued and is preparing to hand over investing duties to Greg Abel.

BCpC - Reported unit sales up 6%, revenue up 15%, record market share, and positive outlook for 2026
BRK.A - Strong operating results but cautious investment approach, with no stock buybacks and net stock selling

#cash #market valuation #stock selling #Warren Buffett #investment strategy

3 Must-Own Stocks for the Driverless Vehicle Revolution

The Motley Fool • Daniel Miller

3 Must-Own Stocks for the Driverless Vehicle Revolution

11/08/2025 01:14 PM • The driverless vehicle market is projected to reach $13 trillion by 2030, with three key stocks positioned to benefit: Ambarella, Nvidia, and QuantumScape. Each company offers unique technological advantages in autonomous vehicle development, from AI processing to computing platforms and advanced battery technology.

AMBA - Strong edge AI capabilities, expanding serviceable addressable market from $5.5B to $12.9B by 2031, and well-positioned in automotive AI applications

#autonomous vehicles #driverless technology #electric vehicles #AI #battery innovation

557,006 OshKosh (OSK) Shares Worth $63.2 Million Sold by SG Capital

The Motley Fool • Cory Renauer

557,006 OshKosh (OSK) Shares Worth $63.2 Million Sold by SG Capital

11/08/2025 01:08 PM • SG Capital Management LLC completely exited its stake in Oshkosh Corporation, selling all 557,006 shares in the third quarter of 2025. The sale represents a significant portfolio change, with the company previously holding OSK as its second-largest holding.

OSK - Stock has slightly underperformed the market (8.2% gain vs S&P 500's 12.7%), and the company adjusted its earnings outlook, indicating some economic uncertainty

#institutional investor #stock sale #portfolio management #specialty vehicles

Ferrari Stock Looks Expensive -- or Does It?

The Motley Fool • Lawrence Nga

Ferrari Stock Looks Expensive -- or Does It?

11/08/2025 01:05 PM • Ferrari's stock appears expensive at 41 times earnings, but its unique luxury brand model, high profitability, and scarcity-driven business strategy suggest the premium valuation might be justified for long-term investors.

RACE - High margins (38.3% EBITDA), strong brand power, consistent cash flow growth, and ability to maintain pricing power through limited production

#luxury brand #automotive #premium valuation #scarcity #electrification

Prediction: This Supercharged Growth Stock Will Join Nvidia, Apple, Microsoft, and Alphabet in the $3 Trillion Club Before 2028

The Motley Fool • Danny Vena

Prediction: This Supercharged Growth Stock Will Join Nvidia, Apple, Microsoft, and Alphabet in the $3 Trillion Club Before 2028

11/08/2025 01:02 PM • Broadcom is predicted to reach a $3 trillion market cap by 2028 due to its critical role in the AI ecosystem, with strong growth in AI semiconductors and data center solutions driving its potential expansion.

FLEX - Mentioned as a leading market player without specific recent developments
AVGO - Strong AI-related revenue growth, record quarterly earnings, expanding customer base including OpenAI, and projected 60%+ AI segment growth

#AI #semiconductors #market cap #data centers #technology

Why Iren Limited Rallied Again in October

The Motley Fool • Billy Duberstein

Why Iren Limited Rallied Again in October

11/08/2025 12:30 PM • Iren Limited experienced significant stock growth in October, securing AI cloud contracts, raising $1 billion in convertible notes, and announcing a massive $9.7 billion five-year deal with Microsoft that could expand its annual recurring revenue to $2.5 billion.

IREN - Stock rallied 29.4% in October, secured major cloud contracts, raised significant capital, and signed a transformative deal with Microsoft expanding potential revenue

#AI #cloud computing #data centers #GPUs #technology investment

QLD and SPXL Offer Distinct Leverage for Growth Investors

The Motley Fool • Jake Lerch

QLD and SPXL Offer Distinct Leverage for Growth Investors

11/08/2025 12:21 PM • Two leveraged ETFs, QLD and SPXL, provide different approaches to amplifying market returns. QLD offers 2x Nasdaq-100 exposure with a tech focus, while SPXL provides 3x S&P 500 leverage across broader sectors. Both have significantly outperformed the S&P 500 index over five years.

QLD - Delivers strong 5-year returns of 252% with a CAGR of 28.6%, heavily weighted in technology stocks with top holdings in leading tech companies

#leveraged ETFs #market returns #index tracking #investment strategy

FLR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Fluor Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – FLR

GlobeNewswire Inc. • Rosen Law Firm

FLR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Fluor Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – FLR

11/08/2025 12:21 PM • Rosen Law Firm is investigating a potential securities class action against Fluor Corporation for allegedly making false and misleading statements about project costs and financial guidance during February 18-July 31, 2025.

GOOGL - Mentioned as previous employer of new CTO, with no negative implications
FLR - The lawsuit alleges the company made false statements about project costs, financial guidance, and risk mitigation strategies, which potentially misled investors about the company's true financial condition

#securities lawsuit #class action #investor rights #financial disclosure

e.l.f Beauty Shares Plunge. Should Investors Buy the Stock on the Dip or Stay Away?

The Motley Fool • Geoffrey Seiler

e.l.f Beauty Shares Plunge. Should Investors Buy the Stock on the Dip or Stay Away?

11/08/2025 12:20 PM • e.l.f. Beauty reported Q2 fiscal 2026 results with lower-than-expected guidance, experiencing revenue challenges due to tariffs and shipping adjustments. Despite short-term setbacks, the company maintains long-term growth potential, particularly with its Rhode acquisition.

ELF - Stock dropped 40% year-to-date, missed revenue expectations, but has strong long-term growth opportunities and trades at an attractive valuation

#beauty #cosmetics #tariffs #earnings #Rhode #market share

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

GlobeNewswire Inc. • Vor Bio

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

11/08/2025 11:45 AM • Telitacicept demonstrated a 55% reduction in proteinuria and statistically significant improvements in kidney function during a Phase 3 clinical trial for IgA Nephropathy in China, with a favorable safety profile.

SCS - The company is being acquired, with ongoing negotiations and procedural steps being taken to facilitate the merger
VOR - Successfully achieved primary and secondary endpoints in clinical trial, demonstrating potential therapeutic effectiveness of telitacicept

#telitacicept #IgA Nephropathy #clinical trial #proteinuria #kidney function

ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages Avantor, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AVTR

GlobeNewswire Inc. • Rosen Law Firm

ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages Avantor, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AVTR

11/08/2025 11:35 AM • Rosen Law Firm filed a class action lawsuit against Avantor, alleging misrepresentation of competitive positioning and business prospects during the period of March 5, 2024 to October 28, 2025.

AVTR - The lawsuit claims the company misrepresented its competitive positioning, experienced negative effects from increased competition, and made materially false statements about its business operations and prospects

#securities lawsuit #class action #investor rights #stock misrepresentation

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

GlobeNewswire Inc. • Monte Rosa Therapeutics

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

11/08/2025 11:30 AM • Monte Rosa Therapeutics presented preclinical data on MRT-8102, a molecular glue degrader targeting NEK7, which shows potential in treating cardiovascular and cardiometabolic diseases by modulating the NLRP3 inflammasome pathway.

TGT - Mentioned as a platform for wishlist donations, with no significant positive or negative context
GLUE - Company presented promising preclinical data demonstrating potential breakthrough in treating inflammatory diseases, with initial Phase 1 study on track and unique approach to targeting cardiovascular inflammation

#molecular glue degrader #NEK7 #NLRP3 inflammasome #cardiovascular disease #cardiometabolic disease

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

GlobeNewswire Inc. • Tenaya Therapeutics

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

11/08/2025 11:25 AM • Tenaya Therapeutics announced promising interim clinical results for TN-201, a gene therapy targeting MYBPC3-associated hypertrophic cardiomyopathy, showing improved biomarkers, reduced hypertrophy, and manageable safety profile in early-stage trials.

TNYA - Presented promising early clinical trial results with positive safety and efficacy signals for TN-201 gene therapy, showing improvements in multiple disease parameters and no significant adverse events

#gene therapy #hypertrophic cardiomyopathy #clinical trial #MYBPC3 #cardiovascular research

3 Cryptocurrencies That Could Make Big Moves in 2026

The Motley Fool • Dominic Basulto

3 Cryptocurrencies That Could Make Big Moves in 2026

11/08/2025 11:17 AM • The article explores potential cryptocurrency opportunities in real-world asset tokenization, highlighting Chainlink, Ondo, and World Liberty Financial as key players in this emerging market trend for 2026.

GS - Serving as joint sponsor, overall coordinator, and global coordinator for the IPO, indicating a standard professional engagement
GLNK - Down 30% in 2025 but considered a top market cap RWA token with strong potential for real-world asset tokenization infrastructure

#cryptocurrency #tokenization #blockchain #real-world assets #digital finance

IGEL läutet neue Ära der EUC-Transformation und vertrauenswürdigen Endpunktsicherheit ein

GlobeNewswire Inc. • Igel

IGEL läutet neue Ära der EUC-Transformation und vertrauenswürdigen Endpunktsicherheit ein

11/08/2025 11:07 AM • IGEL hosted its flagship event in Frankfurt, showcasing new endpoint security solutions focused on Zero Trust architecture, prevention-oriented security, and digital workplace transformation with key technology partners.

GSpA - Serving as joint sponsor, overall coordinator, and global coordinator for the IPO, indicating a standard professional engagement
MSFT - Mentioned as a key technology partner collaborating on innovative endpoint solutions

#Zero Trust #Endpoint Security #Digital Workplace #Cybersecurity #Adaptive Desktop

AGL Investor News: If You Have Suffered Losses in agilon health, inc. (NYSE: AGL), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

GlobeNewswire Inc. • Rosen Law Firm

AGL Investor News: If You Have Suffered Losses in agilon health, inc. (NYSE: AGL), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

11/08/2025 10:46 AM • Rosen Law Firm is investigating potential securities claims for agilon health shareholders after the company suspended its 2025 financial guidance, causing a 51.5% stock price drop on August 5, 2025.

GSpD - Serving as joint sponsor, overall coordinator, and global coordinator for the IPO, indicating a standard professional engagement
AGL - Company suspended full-year financial guidance, acknowledged more severe industry headwinds than previously expected, and experienced a significant 51.5% stock price decline

#securities claims #investor losses #financial guidance #stock price drop

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

GlobeNewswire Inc. • Regeneron Pharmaceuticals, Inc.

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

11/08/2025 10:46 AM • Regeneron announced positive Phase 2 trial results for two novel factor XI antibodies (REGN7508Cat and REGN9933A2) that demonstrate robust anti-clotting effects with minimal bleeding risk in patients undergoing total knee replacement surgery.

GSpC - Serving as joint sponsor, overall coordinator, and global coordinator for the IPO, indicating a standard professional engagement
REGN - Successfully demonstrated promising Phase 2 trial results for novel antibodies with potential to improve anticoagulation therapy, showing reduced venous thromboembolism rates and minimal bleeding risks

#factor XI #antibodies #anticoagulation #venous thromboembolism #clinical trials